Cargando…

Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report

For advanced hepatocellular carcinoma (HCC) patients, liver transplantation (LT) is an optimal treatment with limitation of high risk of tumor recurrence related to the immunosuppressive chemotherapy as usually recommended. In this study, a 29-year-old man suffered from HCC recurrence after LT. He u...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Silun, Wu, Zhengyi, Zhou, Liang, Liang, Yingqing, Wang, Xiaohua, Niu, Lizhi, Xu, Kecheng, Chen, Jibing, Zhang, Mingjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207256/
https://www.ncbi.nlm.nih.gov/pubmed/30498359
http://dx.doi.org/10.2147/OTT.S166962
_version_ 1783366491375140864
author Xie, Silun
Wu, Zhengyi
Zhou, Liang
Liang, Yingqing
Wang, Xiaohua
Niu, Lizhi
Xu, Kecheng
Chen, Jibing
Zhang, Mingjie
author_facet Xie, Silun
Wu, Zhengyi
Zhou, Liang
Liang, Yingqing
Wang, Xiaohua
Niu, Lizhi
Xu, Kecheng
Chen, Jibing
Zhang, Mingjie
author_sort Xie, Silun
collection PubMed
description For advanced hepatocellular carcinoma (HCC) patients, liver transplantation (LT) is an optimal treatment with limitation of high risk of tumor recurrence related to the immunosuppressive chemotherapy as usually recommended. In this study, a 29-year-old man suffered from HCC recurrence after LT. He underwent radiotherapy (total dose: 45 Gy) but had no significant response. Then, he received iodine-125 seed implantation combined with allogenic natural killer (NK) cell immunotherapy. Liver function, immune function, circulating tumor cell counts and computed tomography scans were evaluated to determine the clinical effect. We found that this combined treatment produced enhanced immune function of the patient and reduction in tumor size. This is the first report of an efficacy and safety study about clinical regimen comprising allogenic NK cell immunotherapy combined with iodine-125 seed implantation for the treatment of HCC recurrence after LT.
format Online
Article
Text
id pubmed-6207256
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62072562018-11-29 Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report Xie, Silun Wu, Zhengyi Zhou, Liang Liang, Yingqing Wang, Xiaohua Niu, Lizhi Xu, Kecheng Chen, Jibing Zhang, Mingjie Onco Targets Ther Case Report For advanced hepatocellular carcinoma (HCC) patients, liver transplantation (LT) is an optimal treatment with limitation of high risk of tumor recurrence related to the immunosuppressive chemotherapy as usually recommended. In this study, a 29-year-old man suffered from HCC recurrence after LT. He underwent radiotherapy (total dose: 45 Gy) but had no significant response. Then, he received iodine-125 seed implantation combined with allogenic natural killer (NK) cell immunotherapy. Liver function, immune function, circulating tumor cell counts and computed tomography scans were evaluated to determine the clinical effect. We found that this combined treatment produced enhanced immune function of the patient and reduction in tumor size. This is the first report of an efficacy and safety study about clinical regimen comprising allogenic NK cell immunotherapy combined with iodine-125 seed implantation for the treatment of HCC recurrence after LT. Dove Medical Press 2018-10-25 /pmc/articles/PMC6207256/ /pubmed/30498359 http://dx.doi.org/10.2147/OTT.S166962 Text en © 2018 Xie et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Report
Xie, Silun
Wu, Zhengyi
Zhou, Liang
Liang, Yingqing
Wang, Xiaohua
Niu, Lizhi
Xu, Kecheng
Chen, Jibing
Zhang, Mingjie
Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report
title Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report
title_full Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report
title_fullStr Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report
title_full_unstemmed Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report
title_short Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report
title_sort iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207256/
https://www.ncbi.nlm.nih.gov/pubmed/30498359
http://dx.doi.org/10.2147/OTT.S166962
work_keys_str_mv AT xiesilun iodine125seedimplantationandallogenicnaturalkillercellimmunotherapyforhepatocellularcarcinomaafterlivertransplantationacasereport
AT wuzhengyi iodine125seedimplantationandallogenicnaturalkillercellimmunotherapyforhepatocellularcarcinomaafterlivertransplantationacasereport
AT zhouliang iodine125seedimplantationandallogenicnaturalkillercellimmunotherapyforhepatocellularcarcinomaafterlivertransplantationacasereport
AT liangyingqing iodine125seedimplantationandallogenicnaturalkillercellimmunotherapyforhepatocellularcarcinomaafterlivertransplantationacasereport
AT wangxiaohua iodine125seedimplantationandallogenicnaturalkillercellimmunotherapyforhepatocellularcarcinomaafterlivertransplantationacasereport
AT niulizhi iodine125seedimplantationandallogenicnaturalkillercellimmunotherapyforhepatocellularcarcinomaafterlivertransplantationacasereport
AT xukecheng iodine125seedimplantationandallogenicnaturalkillercellimmunotherapyforhepatocellularcarcinomaafterlivertransplantationacasereport
AT chenjibing iodine125seedimplantationandallogenicnaturalkillercellimmunotherapyforhepatocellularcarcinomaafterlivertransplantationacasereport
AT zhangmingjie iodine125seedimplantationandallogenicnaturalkillercellimmunotherapyforhepatocellularcarcinomaafterlivertransplantationacasereport